

"Impact Vizor"

vi·sor /'vīzər/

(1) A HighWire product to understand article performance

(2) The first of a series of analytics "Vizors" from HighWire to deliver editorial and business insight to decision-makers

(3) Available to publishers not hosted by HighWire

Lorraine Ellery, Director Business Development November 2015

Impact Vizor: Data-driven Insight into Some of Publishing's Big Questions



- Rejected Articles
 - Who publishes my rejected articles?
 - Am I rejecting high-impact articles?
- Published Articles
 - Which articles are driving my impact up, or down?
 - Which types of articles are resonating?
 - Are this year's articles higher impact than last year's?
- Cohort Articles
 - What are the trending topics in my fields?
 - And who is publishing them?

Why Did We Build Impact Vizor? How Does it Advance Understanding of Impact?




- Integration
 - You see impact 'sliced and diced' in categories that are meaningful for your publishing program
- In time
 - Measurements are accumulated rapidly and continuously
- Insight
 - Visual, point and click tools are accessible to people who need the information



Visual Insight


anuscripts





Visualizations of data

- provide direct access to information
- by people who need it,
- in a way they can use it.




Why Did We Build Impact Vizor? What Use Cases Drive Impact Vizor Value?



- New journals under consideration
- New journals being started
- New editors coming in to existing journals
- New and revised policies and scope for journals
 - Add journal sections
 - Addition of journal sections, etc.
 - Spin off of journal sections into journals
- New and evolving disciplines
- Volatility in Impact Factor, change in direction of IF
- Desire for information in time to make decisions

Inside Impact Vizor





- 1. Rejected-Article Tracker (RAT) ← released
- 2. Hot-Article Tracker (HAT) ← released
- 3. Hot-Object Tracker (HOT) ← released
- 4. Citation Distribution Surveyor (CDS) ← released
- 5. Cohort Comparator (CC)** ← released
- 6. Section-Performance Analyzer (SPA) ← November
- 7. Advance Correlator of Citation & Usage (ACCU) ← December

in rollout in development in design



The

Rejected Article Tracker

with thanks to Am Soc. Hematology for allowing us to show data from Blood


The Components of the RAT



Overview



Manuscript Inspector



Editor Overview - By Status



Category Overview - By Status



The Rejected-Article Tracker

billiactional diversity is a critical early event in the development of

(afterly and clinical efficacy of rapidly generated trivings-directed

code as beginned for Adenovirus, EBV and CMV infections after

perferitivenic Syndrome Macrophage Activation Syndrome, SWs

Disease, Sapite Shinti. Calastrophic Arlighospholpal Syndrone and

myeliums and precisites the development of clinical symptoms

anti-CDDE finance

Mogames HSCT



31

27

27

Where do your rejected articles get published?

How much do they get cited?



3/18/2013

1/28/2013

3/11/2013

Published &

Published &

Published &

Cited

Cited

7/2/2013

1/1/2013

6/20/2013

Reject Reason 3

Reject Reason 3

Reject Reason 3




The

Published Article Trackers

with thanks to Am Soc. Hematology for allowing us to show data from Blood

The Hot-Article Tracker: What Articles are "Trending" Now?





Set one or more of the filters. This will update the chart shown below.

Hot Articles									
Article Brief	TOC Section	Collection	Cites / Month	Cites					
Idelalisib, an inhibitor Brown,J. R. 3-10-2014	Clinical Trials And Observations	Free Research Articles	2.9	50	50.0				
Antibody-modified T cells Maus,M. V. 2-27-2014	Antibody Derivatives As New Therapeutics For Hematologic Malignancies	Free Research Articles	2.7	48	48.0				
Clonal evolution and clin Lundberg,P. 1-29-2014	Myeloid Neoplasia	Free Research Articles	1.3	24	24.0				
Idelalisib, a selective i Flinn,I. W. 3-10-2014	Clinical Trials And Observations	Free Research Articles	1.4	24	24.0				
Current concepts in the d Lee,D. W. 5-29-2014	How I Treat	How I Treat	1.5	23	23.0				
TET2 mutations predict re Bejar,R. 9-15-2014	Myeloid Neoplasia	Free Research Articles	2.1	23	23.0				

The Hot-Object Tracker: What Group of Articles Accrues Citations Most Rapidly?





Set one or more of the filters. This will update the chart shown below.

Group By	Group Cites	Group Articles	Group Cites / Article	Group Cites / Published Months	Measure By
Antibody Derivatives As New Therapeutics For Hematologic Malignancies	97	3	32.3	1.80	
Cancer-Associated Thrombotic Disease	159	5	31.8	1.28	
Cme Article	2,451	63	38.9	1.12	
Blood Spotlight	62	3	20.7	1.00	
Perspectives	3,854	105	36.7	0.98	
Clinical Trials And Observations	33,369	813	41.0	0.97	

The Citation Distribution Surveyor



- Do 30% of my articles account for 70% of my citations?
- How many of my articles are cited more than 20 times?
- How rapidly do my articles accrue citations?






The Section-Performance Analyzer:

HighWire

Are New Articles Cited More or Less than Previous Ones?



Viewing Multiple Measures of Impact:



Correlating Citation and Usage Patterns What's Cited vs. Used vs. Discussed

- Impact comes in several dimensions
 - Citations (scientific 'resonance')
 - Usage (readership volume)
 - Social (community engagement)
- Look at all of these together (mockup)

Group By	Group Cites	Group Articles	Group Cites / Article	Measure By	ure By	Measure By
Antibody Derivatives As New Therapeutics For Hematologic Malignancies	97	3	32.3			
Cancer-Associated Thrombotic Disease	159	5	31.8			
Cme Article	2,451	63	38.9			
Blood Spotlight	62	3	20.7			
Perspectives	3,854	105	36.7			
Clinical Trials And Observations	33,369	813	41.0			

Article-Citation Inspector

10/1/2010

The Nucleolus under Stress




Molecular Cell

Is this article continuing to be cited?

Which fields and journals are citing it?

Lets you evaluate an individual article's citation sources and citation longevity, as well as its contribution to overall impact



The 'Impact' of Understanding Impact



Publishers and editors will be able to...

- Know the research merit of the articles they accept and reject
- Know who is accepting your rejected articles, and citing them
- See whether this year's articles are having more impact than previous years' articles
- See which articles, topics, and authors are getting research attention most rapidly
- Identify likely high-impact articles before they are cited
- Know how a discipline is shifting
- Know all of this in a timely way

Publishers and editors will have evidence for taking action



"Impact Vizor has quickly become an invaluable tool enabling us to discover interesting trends. We are impressed with the speed and clarity of the insights available to our editorial team now."

Keith Gigliello, Digital Manager, Publishing, American Society of Hematology

Want to know even more? lellery@highwire.org